This article was originally published in The Gray Sheet
Executive SummaryDatascope's collagen-based Vasoseal is not included on the Health Care Financing Administration's list of devices eligible for reimbursement under the hospital outpatient prospective payment system. Competitor Kensey-Nash's Angioseal closure device is included on the list. St. Jude acquired marketing and manufacturing rights to Angioseal in February 1999 (1"The Gray Sheet" Feb. 8, 1999, p. 15). "The Gray Sheet" previously reported the device was not on the list
You may also be interested in...
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.